Harry P. Erba, MD, PhD, on AML: Early Study Results on Vadastuximab Talirine
2016 ASH Annual Meeting & Exposition
Harry P. Erba, MD, PhD, of the University of Alabama at Birmingham, discusses phase Ib findings on vadastuximab talirine in combination with 7+3 induction therapy for patients with newly diagnosed AML (Abstract 211).
Robert E. Marcus, MD, of Kings College Hospital, discusses study findings on obinutuzumab-based induction and maintenance in patients with previously untreated disease (Abstract 6).
Catherine Thieblemont, MD, PhD, of Hôpital Saint-Louis and INSERM, and Julie Vose, MD, MBA, of the University of Nebraska Medical Center, discuss phase III trial findings on lenalidomide maintenance in elderly patients with DLBCL treated with R-CHOP in the first-line setting (Abstract 471).
Syed A. Abutalib, MD, of Cancer Treatment Centers of America, and Alex F. Herrera, MD, of City of Hope National Medical Center, discuss study findings that suggest allogeneic stem cell transplantation may overcome the chemoresistance of double-hit/double-expressor tumors (Abstract 830).
Smita Bhatia, MD, MPH, and Jessica Wu, BA, both of the University of Alabama at Birmingham, discuss long-term morbidity and mortality experienced by chronic myeloid leukemia patients after allogeneic hematopoietic cell transplantation (Abstract 823).
Catherine Thieblemont, MD, PhD, of Hôpital Saint-Louis and INSERM, discusses in French phase III trial findings on lenalidomide maintenance in elderly patients with DLBCL treated with R-CHOP in the first-line setting (Abstract 471).